Company intelligence / Profile preview
AV7 Ltd
Not specified, Not specified, United Kingdomav7.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AV7 Ltd has completed a Phase 1 clinical trial for its lead candidate K1‑70, a thyroid stimulating hormone receptor antagonist monoclonal antibody. The study evaluated safety and tolerability in patients with Graves’ disease. No further clinical results are publicly available at this time.[1]
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Monoclonal antibodies (mAbs) (K1-70 is a TSH receptor antagonist antibody)[1]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on AV7 Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AV7 Ltd.